Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.58 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2173603 | 0.91 | SGMS1 (0.49) | TRPV1IGF1RHIF1ATP53THRB | |
| SCHEMBL19882503 | 0.90 | TRPV1 (0.46) | TRPV1IGF1RHIF1ATP53THRB | |
| SCHEMBL12407097 | 0.90 | TRPV1 (0.45) | TRPV1IGF1RHIF1ATP53GAA | |
| SCHEMBL4397597 | 0.90 | TRPV1 (0.45) | TRPV1HIF1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5668546 | 0.90 | IGF1R (0.49) | TRPV1IGF1RHIF1ATP53THRB | |
| SCHEMBL4396904 | 0.90 | MAPT (0.48) | TRPV1TP53THRBGAAHTT | |
| SCHEMBL10126403 | 0.89 | IGF1R (0.52) | TRPV1IGF1RHIF1ATP53THRB | |
| SCHEMBL4385586 | 0.89 | IGF1R (0.48) | TRPV1IGF1RHIF1ATP53THRB | |
| SCHEMBL5668870 | 0.89 | IGF1R (0.51) | TRPV1IGF1RHIF1ATP53GAA | |
| SCHEMBL4387708 | 0.89 | TRPV1 (0.44) | TRPV1IGF1RHIF1ATP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932589-B2 | EML4-ALK fusion gene | ASTELLAS PHARMA INC. (JP) | 2018-04-03 | — | — | US | disclosed |
| US-20180066266-A1 | EML4-ALK FUSION GENE | ASTELLAS PHARMA INC. (JP) | 2018-03-08 | — | — | US | disclosed |
| EP-3009428-B1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2018-02-21 | — | — | EP | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-2428508-B9 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-3009428-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-2428508-B1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-20150184161-A1 | EML4-ALK FUSION GENE | ASTELLAS PHARMA INC. (JP) | 2015-07-02 | — | — | US | disclosed |
| US-9029521-B2 | EML4-ALK fusion gene | ASTELLAS PHARMA INC. (JP) | 2015-05-12 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-1914240-B1 | EML4-ALK fusion gene | ASTELLAS PHARMA INC (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-2116553-A1 | EML4-ALK fusion gene | Astellas Pharma Inc. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-7605131-B2 | EML4-ALK fusion gene | ASTELLAS PHARMA INC. (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090099193-A1 | EML4-ALK FUSION GENE | ASTELLAS PHARMA INC. (JP) | 2009-04-16 | — | — | US | disclosed |
| EP-1914240-A1 | EML4-ALK fusion gene | Astellas Pharma Inc. (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080090776-A1 | EML4-ALK FUSION GENE | ASTELLAS PHARMA INC. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | TRPV1 2373/4885IGF1R 47/4885CSNK1D 2411/4885 |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | TRPV1 3477/4885IGF1R 367/4885CSNK1D 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.